Amyloid Deposition in the Pancreas in Diabetes

The deposition of amyloid in the pancreas, particularly through the aggregation of islet amyloid polypeptide (IAPP), plays a critical role in the development of type 2 diabetes. Misfolded IAPP can aggregate into harmful amyloid fibrils, which disrupt the function of pancreatic beta cells and trigger their apoptosis. This accumulation interferes with the normal secretion of insulin, leading to heightened levels of hyperglycemia and accelerating the disease's progression. Studies show a direct correlation between amyloid presence in pancreatic islets and the extent of beta-cell loss and insulin resistance. Gaining insight into the mechanisms behind amyloid formation and its impact on pancreatic function is vital for creating targeted therapies aimed at preventing or reversing amyloid accumulation. Ongoing research into substances that can either inhibit the formation of amyloid or facilitate its removal presents promising opportunities for novel interventions in diabetes care.